Avellino
Michael Shuler has a vast experience in the ophthalmic industry, holding various executive positions in different companies. Currently, michael is the President of their own consulting company, Shuler Group, where michael provides ophthalmic business consulting services. michael also serves as the VP of Strategic Accounts at Avellino Lab USA, managing key accounts to enhance the company's presence in the U.S market. Furthermore, Michael has a background in sales and business development, having worked for companies like Tear Science, WaveLight, and VISX. michael holds a Tuck Executive Program degree in Business Administration and Management from Dartmouth College and a degree in Business Administration from the University of Hawai'i.
This person is not in any offices
Avellino
Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea and Japan. Its world class CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV. Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.